SMMT — Summit Therapeutics Inc.

Is SMMT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Summit Therapeutics Inc. (SMMT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $11.82. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Summit Therapeutics Inc. (SMMT) faces a material near-term setback after the FDA issued a Complete Response Letter for its lead lung cancer asset, citing insufficient overall survival data. The company is highly concentrated on this program, so regulatory uncertainty sharply increases valuation risk and likely shortens cash runway, making financing/dilution a near-term issue. Negative newsflow and social sentiment have already pressured the share price, and market conditions favor defensive, large-cap healthcare names over small-cap biotech with binary catalysts. Potential upside scenarios include additional analyses, a successful appeal or re-submission based on supplementary data, or a partnership/acquisition; however, timelines are uncertain and could take many quarters to resolve, keeping risk elevated in the near term.

Key factors

  • FDA issued a Complete Response Letter (CRL) for ivonescimab BLA citing insufficient overall survival data, materially reducing near-term approval probability for the lead asset.
  • Lead-asset concentration: company valuation and near-term prospects are heavily dependent on ivonescimab, increasing downside from a regulatory setback.
  • Cash runway and financing pressure likely to increase after the CRL, raising dilution risk if additional trials or analyses are required.
  • Negative social and news sentiment following the CRL and related 8-K, which can accelerate investor outflows and depress stock liquidity/valuation.
  • Limited observable revenue streams; potential paths to value now hinge on additional clinical data, appeal/response strategy with FDA, or strategic partnerships/acquisition.
  • Insider Form 4 activity indicates some management/insider movement, but this is insufficient to offset the regulatory and program risk in the short term.
  • Broader market context shows risk-off flows and defensive sector preference, reducing appetite for binary-risk small-cap biotech exposure in the near term.

Risks

  • Further clinical or regulatory failures for ivonescimab or other pipeline programs, which would further erode valuation.
  • Need to finance operations through equity or convertible issuance, causing significant dilution to existing shareholders.
  • Protracted discussions with FDA or requirement for additional OS trials could extend timelines by multiple quarters/years.
  • Competitive dynamics in lung cancer (other targeted therapies, immuno-oncology) could limit commercial opportunity even if approval is eventually achieved.
  • Adverse market sentiment and sector rotation away from small-cap biotech could impair access to capital and strategic partners.
  • Potential legal, manufacturing, or commercial-readiness issues that emerge during a prolonged regulatory process.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for SMMT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.